NASDAQ:HALOHalozyme Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $28.97 -0.30 (-1.02 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$28.61Now: $28.97▼$29.4850-Day Range$23.15MA: $26.87▼$29.2752-Week Range$12.71Now: $28.97▼$29.64Volume745,592 shsAverage Volume1.56 million shsMarket Capitalization$3.93 billionP/E RatioN/ADividend YieldN/ABeta1.8 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Halozyme Therapeutics, Inc., a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. The company's products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its pipeline include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs in subcutaneous urography; and to enhance resorption of radiopaque agents. The company also develops PEGPH20, a therapy that is in Phase III clinical trial for pancreatic ductal adenocarcinoma; in Phase Ib clinical trial for non-small cell lung cancer; in Phase Ib/II clinical trial for patients with previously treated metastatic pancreatic ductal adenocarcinoma; in Phase Ib/II clinical trial for patients with gastric cancer; and in Phase Ib/II for cholangiocarcinoma and gall bladder cancer. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; and ARGENX BVBA. The company was founded in 1998 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 2.4 Analyst's Opinion Consensus RatingHalozyme Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $29.80, Halozyme Therapeutics has a potential upside of 2.9% from its current price of $28.97.Amount of Analyst CoverageHalozyme Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.7 Community Rank Outperform VotesHalozyme Therapeutics has received 440 “outperform” votes. (Add your “outperform” vote.)Underperform VotesHalozyme Therapeutics has received 389 “underperform” votes. (Add your “underperform” vote.)Community SentimentHalozyme Therapeutics has received 53.08% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Vote “Outperform” if you believe HALO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HALO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldHalozyme Therapeutics does not currently pay a dividend.Dividend GrowthHalozyme Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Halozyme Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $857,131.00 in company stock.Percentage Held by InsidersOnly 2.60% of the stock of Halozyme Therapeutics is held by insiders.Percentage Held by Institutions95.37% of the stock of Halozyme Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Halozyme Therapeutics are expected to grow by 93.33% in the coming year, from $0.75 to $1.45 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Halozyme Therapeutics is -52.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Halozyme Therapeutics is -52.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHalozyme Therapeutics has a P/B Ratio of 45.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.60 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:HALO Previous Symbol CUSIP40637H10 CIK1159036 Webwww.halozyme.com Phone858-794-8889Debt Debt-to-Equity Ratio6.66 Current Ratio11.14 Quick Ratio10.15Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio38.63 P/E GrowthN/A Sales & Book Value Annual Sales$195.99 million Price / Sales20.08 Cash FlowN/A Price / Cash FlowN/A Book Value$0.63 per share Price / Book45.98Profitability EPS (Most Recent Fiscal Year)($0.50) Net Income$-72,240,000.00 Net Margins-48.75% Return on Equity-48.92% Return on Assets-17.36%Miscellaneous Employees281 Outstanding Shares135,815,000Market Cap$3.93 billion Next Earnings Date8/10/2020 (Confirmed) OptionableOptionable $28.97 -0.30 (-1.02 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive HALO News and Ratings via Email Sign-up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Halozyme Therapeutics (NASDAQ:HALO) Frequently Asked Questions How has Halozyme Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Halozyme Therapeutics' stock was trading at $18.22 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, HALO shares have increased by 59.0% and is now trading at $28.97. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Halozyme Therapeutics? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Halozyme Therapeutics. When is Halozyme Therapeutics' next earnings date? Halozyme Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Halozyme Therapeutics. How can I listen to Halozyme Therapeutics' earnings call? Halozyme Therapeutics will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available. How were Halozyme Therapeutics' earnings last quarter? Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.02) by $0.02. The biopharmaceutical company earned $25.30 million during the quarter, compared to the consensus estimate of $42.96 million. Halozyme Therapeutics had a negative net margin of 48.75% and a negative return on equity of 48.92%. The firm's revenue for the quarter was down 55.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.01 EPS. View Halozyme Therapeutics' earnings history. What guidance has Halozyme Therapeutics issued on next quarter's earnings? Halozyme Therapeutics updated its FY20 earnings guidance on Monday, May, 11th. The company provided earnings per share guidance of $0.60-0.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.62. The company issued revenue guidance of $230-245 million, compared to the consensus revenue estimate of $239.41 million. What price target have analysts set for HALO? 10 Wall Street analysts have issued 12-month target prices for Halozyme Therapeutics' stock. Their forecasts range from $20.00 to $39.00. On average, they anticipate Halozyme Therapeutics' share price to reach $29.80 in the next twelve months. This suggests a possible upside of 2.9% from the stock's current price. View analysts' price targets for Halozyme Therapeutics. Has Halozyme Therapeutics been receiving favorable news coverage? Press coverage about HALO stock has trended very positive on Friday, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Halozyme Therapeutics earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Halozyme Therapeutics. Who are some of Halozyme Therapeutics' key competitors? Some companies that are related to Halozyme Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Novavax (NVAX). View all competitors. What other stocks do shareholders of Halozyme Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Gilead Sciences (GILD), NIC (EGOV), Micron Technology (MU), Allergan (AGN) and Aegean Marine Petroleum Network (ANW). Who are Halozyme Therapeutics' key executives? Halozyme Therapeutics' management team includes the following people: Dr. Helen I. Torley, Pres, CEO & Director (Age 56)Ms. Laurie D. Stelzer, Sr. VP & CFO (Age 51)Mr. Harry J. Leonhardt, Sr. VP, Gen. Counsel & Corp. Sec. (Age 62)Dr. Dimitrios Chondros, Chief Medical Officer & Sr. VP (Age 54)Mr. Benjamin J. Hickey, Sr. VP & Chief Commercial Officer (Age 44) What is Halozyme Therapeutics' stock symbol? Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO." Who are Halozyme Therapeutics' major shareholders? Halozyme Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include New York State Common Retirement Fund (1.22%), Victory Capital Management Inc. (1.13%), Granite Investment Partners LLC (0.93%), Fisher Asset Management LLC (0.78%), Candriam Luxembourg S.C.A. (0.73%) and AMI Asset Management Corp (0.39%). Company insiders that own Halozyme Therapeutics stock include Dimitrios Chondros, Kenneth J Kelley, Michael J Labarre and Randal J Kirk. View institutional ownership trends for Halozyme Therapeutics. Which major investors are selling Halozyme Therapeutics stock? HALO stock was sold by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Fisher Asset Management LLC, RMB Capital Management LLC, Granite Investment Partners LLC, Trexquant Investment LP, SG Americas Securities LLC, Strs Ohio, and Hancock Whitney Corp. View insider buying and selling activity for Halozyme Therapeutics. Which major investors are buying Halozyme Therapeutics stock? HALO stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., AMI Asset Management Corp, Redwood Investments LLC, Scout Investments Inc., Foundry Partners LLC, Candriam Luxembourg S.C.A., New York State Common Retirement Fund, and First Trust Advisors LP. View insider buying and selling activity for Halozyme Therapeutics. How do I buy shares of Halozyme Therapeutics? Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Halozyme Therapeutics' stock price today? One share of HALO stock can currently be purchased for approximately $28.97. How big of a company is Halozyme Therapeutics? Halozyme Therapeutics has a market capitalization of $3.93 billion and generates $195.99 million in revenue each year. The biopharmaceutical company earns $-72,240,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Halozyme Therapeutics employs 281 workers across the globe. What is Halozyme Therapeutics' official website? The official website for Halozyme Therapeutics is www.halozyme.com. How can I contact Halozyme Therapeutics? Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected]om. This page was last updated on 8/7/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
